CLASS II Drug recall · Reported 1 Oct 2014 · FDA Enforcement Report

Buprenorphine Hydrochloride Injection, CIII recalled by Hospira

Hospira is recalling Buprenorphine Hydrochloride Injection, CIII, 0.3 mg base/mL , 10 Carpuject Sterile, distributed nationwide in the US. The recall was initiated on 9 Sep 2014 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot Number: 35-730-LL, 35-745-LL, Exp: 1 FEB 2015
NDC0409-2012
Quantity recalled373,180 Carpuject units

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-1604-2014
FDA event ID
69163
Recalling firm
Hospira, Lake Forest, IL
Manufacturer
Hospira, Inc.
Classification
Class II
Status
Terminated
Recall initiated
9 Sep 2014
FDA classified
19 Sep 2014
Reported
1 Oct 2014
Type
Voluntary: Firm initiated
Customers notified by
N/A
Reason category
Potency & Assay

Timeline

9 Sep 2014Recall initiated by company
19 Sep 2014Classified by FDA+10 days
1 Oct 2014Published in enforcement report+12 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Failed Impurities/Degradation Specification: Out of Specification results for pseudobuprenorphine impurity at the 9-month stability time point.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Buprenorphine Hydrochloride Injection, CIII, 0.3 mg base/mL ,1 mL, 10 Carpuject Sterile Cartridge Units with Luer Lock, Slim-Paks, F Intramuscular or Intravenous Use, Rx Only, Hospira, Inc., Lake Forest, IL 60045, NDC 0409-2012-32

Where it was distributed

Nationwide

Nationwide

Questions about this recall

Why was it recalled?

Failed Impurities/Degradation Specification: Out of Specification results for pseudobuprenorphine impurity at the 9-month stability time point.

Which lots are affected?

Lot Number: 35-730-LL, 35-745-LL, Exp: 1 FEB 2015

Where was it sold?

Nationwide

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Hospira

All 225

Other Buprenorphine recalls

All 22
ReportedClassRecallCompanyReasonWhere
DrugCLASS IIIBuprenorphine Sublingual Tablets (C-iii), 2 mg recalledBuprenorphineAmerican Health PackagingPackaging DefectsNationwide
DrugCLASS IIBuprenorphine HCl, CIII, Injection, 0.3 mg/mL recalled by Par Health USABuprenorphine HydrochloridePar Health USAOtherNationwide
DrugCLASS IIBuprenorphine Hydrochloride, Injection, 0.3mg/mL recalled by Endo UsaBuprenorphine HydrochlorideEndo USAOtherNationwide
DrugCLASS IIBuprenorphine Hydrochloride Injection recalled by PfizerBuprenorphine HydrochloridePfizerSterilityNationwide
DrugCLASS IIBuprenorphine HCl, Injection, 0.3mg/mL recalled by PAR Sterile ProductsBuprenorphine HydrochloridePAR Sterile ProductsPackaging DefectsNationwide